Use of galantamine to treat vascular dementia [4] (multiple letters)

Lancet

Volumn 360, Issue 9344, 2002, Pages 1512-1513

  Van Gool, W A ^a   Moretti, Rita ^b   Torre, Paola ^b   Antonello, Rodolfo M ^b   Cazzato, Giuseppe ^b   Bava, Antonio ^b   Erkinjuntti, Timo ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF TRIESTE   (Italy)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; CARDIOASPIRIN; CHOLINESTERASE INHIBITOR; GALANTAMINE; RIVASTIGMINE; UNCLASSIFIED DRUG; NOOTROPIC AGENT;

CHOLINERGIC SYSTEM; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; LETTER; MULTIINFARCT DEMENTIA; NAUSEA; PRIORITY JOURNAL; VOMITING; NOTE;

CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; GALANTAMINE; HUMANS; NOOTROPIC AGENTS;

EID: 0037048949     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(02)11449-8     Document Type: Letter

References (5)

1. T Erkinjuntti A Kurz S Gauthier R Bullock S Lilienfeld CV Damaraju Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial Lancet 359 2002 1283 1290
2. R Moretti P Torre RM Antonello G Cazzato Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow up EurJ Neurol 8 2001 361 362
3. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine is safe and effective for at least 22 months in patients with subcortical vascular dementia (VaD), presented at the 2nd International Congress on Vascular Dementia, Salzburg, Austria, Jan 24–27, 2002.
4. M Weinstock Selectivity of cholinesterase inhibition CNS Drugs 12 1999 307 323
5. V Kumar R Anand J Messina R Hartman J Veach An efficacy and safety analysis of Exelon in Alzheimer's disease with concurrent vascular risk factors Eur J Neurol 7 2000 159 169